Review: The role of cetuximab in the treatment of metastatic colorectal cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 4007-4011

  Holubec, Lubos ^a   Liska, Vaclav ^a   Matejka, Vit M ^a   Fiala, Ondrej ^a   Dreslerova, Jana ^a   Mrazkova, Petra ^a   Treska, Vladislav ^a   Finek, Jindrich ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cetuximab; Colorectal cancer; KRAS; Liver metastases; Review

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; COLORECTAL TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS;

EID: 84867017245     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B and Fric P: Colorectal cancer screening in Europe. World J Gastroenterol 15(47): 5907-15, 2009.
2. Ryska M, Pantoflícek J and Dusek L: Surgery for liver metastases of colorecta etiology in Czech Republic: Current National Survey. Rozhl Chir 89(2): 100-108, 2010.
3. McRee AJ and Goldberg RM: Optimal management of metastatic colorectal cancer: current status. Drugs 71(7): 869-884, 2011.
4. Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39(10): 1348-1354, 2003.
5. Chee CE and Sinicrope FA: Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 39(3): 601-613, 2010.
6. Kim ES, Khuri FR and Herbst RS: Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13( 6): 506-513, 2001.
7. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J and Tortora G: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6(9) : 3739-3747, 2000.
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004.
9. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13(12) : 1841-1851, 2002.
10. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P and Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15): 2011-2009, 2011.
11. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417, 2009.
12. Petruzelka L: Targeted biological treatment of solid tumours. Vnitr Lek 57(9) : 740-744, 2011.
13. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH and Siena S: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 29( 33): 5335-5343, 2008.
14. Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S and Lerzo G: Cetuximab plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 9(5) : 282-289, 2010.
15. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J and Cervantes A: Cetuximab administered once every second week to patients with metastatic colorectal cancer: A two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 21(7) : 1537-1545, 2010.
16. Humblet Y, Peeters M and Geldetblom H: Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetics (PK), pharmacodynamics (PD) and efficacy data from the EVEREST study. Eur J Cancer 4(Suppl 5): Abstract 3040, 2007.
17. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2(14): 2311-2319, 2008.
18. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7): 1535-1546, 2011.
19. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R and Cheadle JP: MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783): 2103-2114, 2011.
20. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R and Maughan TS: MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results ofthe randomised phase 3 MRC COIN trial. Lancet Oncol 12(7): 642-653, 2011.
21. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC and Richardson AJ: A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 9(16): 1553-1559, 2011
22. Treska V, Skalický T, Sutnar A and Liska V: Surgical management of the colorectal carcinoma liver metastases. Rozhl Chir 88(2): 69-74, 2009.
23. Leonard GD, Brenner B and Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23(9): 2038-2048, 2005.
24. Kubala E, Petruzelka L and Sedlácková E: Chemotherapy and biological treatment in the complex management of large intestinal and rectal carcinomas. When, why, how?. Rozhl Chir 2009 88(6): 303-307, 2009.
25. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG and Strasberg SM: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200(6): 845-853, 2005.
26. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM and Vauthey JN: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7(8) : 1082-1088, 2003.
27. Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, Jaeck D and Chenard MP: Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 36( 6): 575-582, 2010.
28. Liska V, Treska V and Holubec L: Immediately preoperative use of biological therapy does not influence liver regeneration after large resection - porcine experimental model with monoclonal antibody against epidermal growth factor. In Vivo, 2012 in press.
29. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F and Köhne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1): 38-47, 2010.
30. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I and Cognetti F: Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103(10): 1542-1547, 2010.